Roivant Sciences Ltd. (NASDAQ:ROIV) Receives Consensus Recommendation of "Moderate Buy" from Analysts

Key Points

• Roivant Sciences has a consensus analyst rating of “Moderate Buy”, based on coverage from 12 research firms. Ten analysts rate it a buy, while one each rate it sell and hold.
• Several analysts recently raised their price targets on the stock, with new targets ranging from $34 to $42. The average 12-month target price is about $33.59.
• Insiders have sold shares in recent months, including director sales by Melissa B. Epperly and Daniel Allen Gold. Despite that, institutional investors still own a large majority of the company at 64.76%.

Roivant Sciences Ltd. (NASDAQ:ROIV - Get Free Report) has earned a consensus recommendation of "Moderate Buy" from the twelve research firms that are currently covering the stock, Marketbeat reports. One research analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and ten have given a buy recommendation to the company. The average 12-month target price among analysts that have covered the stock in the last year is $33.5909.

A number of research analysts have recently commented on ROIV shares. TD Cowen increased their price target on Roivant Sciences from $38.00 to $41.00 and gave the company a "buy" rating in a research note on Thursday, May 21st. Citigroup increased their target price on Roivant Sciences from $35.00 to $42.00 and gave the company a "buy" rating in a research report on Thursday, May 21st. Guggenheim lifted their price target on Roivant Sciences from $30.00 to $36.00 and gave the company a "buy" rating in a research note on Tuesday, May 26th. HC Wainwright restated a "buy" rating and set a $34.00 price target on shares of Roivant Sciences in a report on Thursday, May 21st. Finally, Leerink Partners set a $42.00 price objective on Roivant Sciences in a research note on Thursday, May 21st.

Insiders Place Their Bets

In related news, Director Melissa B. Epperly sold 17,750 shares of the business's stock in a transaction on Monday, June 29th. The shares were sold at an average price of $34.38, for a total value of $610,245.00. Following the sale, the director owned 16,474 shares of the company's stock, valued at $566,376.12. The trade was a 51.86% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Daniel Allen Gold sold 12,380 shares of the stock in a transaction on Tuesday, June 30th. The shares were sold at an average price of $35.28, for a total value of $436,766.40. Following the completion of the sale, the director owned 13,689,166 shares of the company's stock, valued at $482,953,776.48. The trade was a 0.09% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 1,855,913 shares of company stock valued at $62,649,633 in the last ninety days. 10.80% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Roivant Sciences

A number of institutional investors have recently made changes to their positions in ROIV. Morgan Stanley lifted its stake in shares of Roivant Sciences by 31.7% in the fourth quarter. Morgan Stanley now owns 58,359,553 shares of the company's stock worth $1,266,402,000 after acquiring an additional 14,036,696 shares during the period. Vanguard Group Inc. boosted its holdings in Roivant Sciences by 8.4% in the fourth quarter. Vanguard Group Inc. now owns 42,059,041 shares of the company's stock valued at $912,681,000 after acquiring an additional 3,254,113 shares during the last quarter. Rubric Capital Management LP increased its position in Roivant Sciences by 14.7% during the 2nd quarter. Rubric Capital Management LP now owns 20,370,336 shares of the company's stock valued at $229,574,000 after purchasing an additional 2,603,260 shares during the period. State Street Corp raised its holdings in Roivant Sciences by 4.8% during the 2nd quarter. State Street Corp now owns 19,773,480 shares of the company's stock worth $222,847,000 after purchasing an additional 911,827 shares during the last quarter. Finally, UBS Group AG raised its holdings in Roivant Sciences by 570.0% during the 4th quarter. UBS Group AG now owns 18,390,792 shares of the company's stock worth $399,080,000 after purchasing an additional 15,645,836 shares during the last quarter. Institutional investors own 64.76% of the company's stock.

Roivant Sciences Price Performance

Shares of NASDAQ:ROIV opened at $35.10 on Friday. Roivant Sciences has a one year low of $10.90 and a one year high of $37.00. The company has a market cap of $25.25 billion, a price-to-earnings ratio of -58.50 and a beta of 1.11. The firm has a 50 day simple moving average of $32.12 and a 200 day simple moving average of $28.58.

About Roivant Sciences

Roivant Sciences is a biopharmaceutical company focused on the development and commercialization of innovative therapies through a network of subsidiary businesses known as “Vants.” Founded in 2014, Roivant acquires or in-licenses clinical-stage assets that have progressed beyond proof of concept and seeks to advance them efficiently toward regulatory approval. By organizing each program into a dedicated subsidiary, the company aims to streamline decision-making, allocate resources more effectively, and accelerate development timelines.

The core activities of Roivant involve identifying promising drug candidates across a range of therapeutic areas, including neurology, rare diseases, immunology, oncology, and women's health.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.